| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 08:31 | Expecting Gilead To Break $70, Outperforming Merck | | 9 | Seeking Alpha |
| 09.02.
| Merck & Co.: Auslaufender Patentschutz wichtiger Umsatzbringer belastet | | 83 | BörseGo |
| Frankfurt/ Detmold (BoerseGo.de) - Die Experten vom "Frankfurter Tagesdienst" empfehlen die Aktie des Pharmakonzerns Merck & Co. vorerst nicht zu kaufen. Es sei mit keiner überdurchschnittlichen Entwicklung...
Mehr lesen zu:
Merck & Co.: Auslaufender Patentschutz wichtiger Umsatzbringer belastet | |
| 09.02.
| Watch for Shares of Merck to Approach Support at $38.04 | | 1 | SmarTrend |
| 09.02.
| Here's 1 Reason Merck Looks Weak | | 3 | Motley Fool |
| 08.02.
| Higher Bleeding Haunts Merck Candidate | | - | Zacks |
| 08.02.
| Bearish Moving Average Cross by Merck | | - | SmarTrend |
| 08.02.
| Merck Vorapaxar meets TRA-2P study endpoints | | 3 | Pharma Bus Review |
| 07.02.
| Merck's Blood Thinner Vorapaxar Meets Endpoint, But Bleeding Risk Persists | | 91 | AFX News |
| WHITEHOUSE STATION (dpa-AFX) - Drug maker Merck & Company Inc. (MRK),
Tuesday said its investigational blood thinner Vorapaxar has met the primary
endpoint of TRA-2P study by significantly...
Mehr lesen zu:
Merck's Blood Thinner Vorapaxar Meets Endpoint, But Bleeding Risk Persists | |
| 07.02.
| Summary Box: Merck reports anti-clot drug data | | - | Yahoo-USA |
| 07.02.
| Merck anti-clot compound again shows bleeding risk | | 1 | Yahoo-USA |
| 07.02.
| UPDATE 1-Merck clot drug meets study goal but bleeding a risk | | - | Reuters.com |
| 07.02.
| Perception, Opportunity in Volatility - Research & Analysis on Human Genome Sciences and Merck & Co., Inc. | | 34 | MarketWire |
| HONG KONG -- (Marketwire) -- 02/07/12 -- This morning, www.MarketFoundations.com announced new reports highlighting Human Genome Sciences (NASDAQ: HGSI) and Merck & Co., Inc. (NYSE: MRK). Free research...
Mehr lesen zu:
Perception, Opportunity in Volatility - Research & Analysis on Human Genome Sciences and Merck & Co., Inc. | |
| 07.02.
| Merck Reports Top-Line Results Of TRA-2P Study Of Vorapaxar | | 43 | AFX News |
| WHITEHOUSE STATION (dpa-AFX) - Merck & Co Inc. (MRK), known as MSD outside
U.S. and Canada, announced the top-line results of the Thrombin Receptor
Antagonist in Secondary Prevention of...
Mehr lesen zu:
Merck Reports Top-Line Results Of TRA-2P Study Of Vorapaxar | |
| 07.02.
| Merck (MRK) Issues Top-Line Results for TRA-2P Study of Vorapaxar | | - | StreetInsider.com |
| 07.02.
| Merck reports positive Phase III results of insomnia drug | | - | Pharma Bus Review |
| 06.02.
| Merck Investors Can Sleep Easier (Not Easy) | | 5 | Motley Fool |
| 06.02.
| Protecting Your Merck Investment | | 1 | Seeking Alpha |
| 06.02.
| ROUNDUP: Merck Plans To File NDA For Insomnia Drug Suvorexant In 2012 | | 108 | AFX News |
| WHITEHOUSE STATION (dpa-AFX) - Drugmaker Merck & Co. Inc. (MRK) said Monday
that based on the positive results from two pivotal Phase III efficacy trials
for its experimental insomnia drug...
Mehr lesen zu:
ROUNDUP: Merck Plans To File NDA For Insomnia Drug Suvorexant In 2012 | |
| 06.02.
| UPDATE 1-Merck to file application this year for insomnia drug | | 2 | Reuters.com |
| 06.02.
| Merck Plans NDA Filing For Potential Sleep Inducing Suvorexant In 2012 | | 47 | AFX News |
| WHITEHOUSE STATION (dpa-AFX) - Merck & Co. Inc. (MRK) said it plans to file
a New Drug Application or NDA for Suvorexant with the U.S. Food and Drug
Administration in 2012. Suvorexant is...
Mehr lesen zu:
Merck Plans NDA Filing For Potential Sleep Inducing Suvorexant In 2012 | |
